Document is current
Any future updates will be listed below
-
Authors
Bailey, Chris
Pich, Oriol https://orcid.org/0000-0002-1956-1882
Thol, Kerstin https://orcid.org/0000-0002-4624-118X
Watkins, Thomas B. K.
Luebeck, Jens https://orcid.org/0000-0003-4391-979X
Rowan, Andrew
Stavrou, Georgia https://orcid.org/0000-0002-8427-5233
Weiser, Natasha E. https://orcid.org/0000-0001-9971-2961
Dameracharla, Bhargavi
Bentham, Robert
Lu, Wei-Ting https://orcid.org/0000-0002-1405-4806
Kittel, Jeanette
Yang, S. Y. Cindy
Howitt, Brooke E. https://orcid.org/0000-0002-0309-6680
Sharma, Natasha
Litovchenko, Maria
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Hung, King L. https://orcid.org/0000-0002-3662-4662
Cornish, Alex J. https://orcid.org/0000-0002-3966-3501
Moore, David A. https://orcid.org/0000-0002-6296-1312
Houlston, Richard S. https://orcid.org/0000-0002-5268-0242
Bafna, Vineet
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
Nik-Zainal, Serena https://orcid.org/0000-0001-5054-1727
Kanu, Nnennaya https://orcid.org/0000-0001-7232-1952
McGranahan, Nicholas
,
Ambrose, J. C.
Arumugam, P.
Bevers, R.
Bleda, M.
Boardman-Pretty, F.
Boustred, C. R.
Brittain, H.
Brown, M. A.
Caulfield, M. J.
Chan, G. C.
Giess, A.
Griffin, J. N.
Hamblin, A.
Henderson, S.
Hubbard, T. J. P.
Jackson, R.
Jones, L. J.
Kasperaviciute, D.
Kayikci, M.
Kousathanas, A.
Lahnstein, L.
Lakey, A.
Leigh, S. E. A.
Leong, I. U. S.
Lopez, F. J.
Maleady-Crowe, F.
McEntagart, M.
Minneci, F.
Mitchell, J.
Moutsianas, L.
Mueller, M.
Murugaesu, N.
Need, A. C.
O’Donovan, P.
Odhams, C. A.
Patch, C.
Perez-Gil, D.
Pereira, M. B.
Pullinger, J.
Rahim, T.
Rendon, A.
Rogers, T.
Savage, K.
Sawant, K.
Scott, R. H.
Siddiq, A.
Sieghart, A.
Smith, S. C.
Sosinsky, A.
Stuckey, A.
Tanguy, M.
Taylor Tavares, A. L.
Thomas, E. R. A.
Thompson, S. R.
Tucci, A.
Welland, M. J.
Williams, E.
Witkowska, K.
Wood, S. M.
Zarowiecki, M.
Flanagan, Adrienne M. https://orcid.org/0000-0002-2832-1303
Mischel, Paul S. https://orcid.org/0000-0002-4560-2211
Jamal-Hanjani, Mariam
Swanton, Charles https://orcid.org/0000-0002-4299-3018
- License Information
-
More Information
Article History
Received: 6 July 2023
Accepted: 24 September 2024
First Online: 6 November 2024
Competing interests
: C.S. acknowledges grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx—collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical and Personalis. C.S. is chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the steering committee chair. C.S. is also co-chief investigator of the NHS Galleri trial financed by GRAIL and a paid member of GRAIL’s scientific advisory board (SAB). C.S. receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, the China Innovation Centre of Roche (formerly the Roche Innovation Centre—Shanghai), Metabomed (until July 2022) and the Sarah Cannon Research Institute. C.S. has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana. C.S. has previously held stock options in Apogen Biotechnologies and GRAIL, and currently has stock options in Epic Bioscience and Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. declares patent applications on methods to detect lung cancer (PCT/US2017/028013), targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA loss of heterozygosity (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912) and methods for lung cancer detection (US20190106751A1). C.S. is an inventor on a European patent application (PCT/GB2017/053289) relating to assay technology to detect tumour recurrence. This patent has been licensed to a commercial entity, and under their terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). N.M. has stock options in and has consulted for Achilles Therapeutics and holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA loss of heterozygosity (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). P.S.M. is a co-founder, chairs the SAB of and has equity interest in Boundless Bio. P.S.M. is also an advisor with equity for Asteroid Therapeutics and is an advisor to Sage Therapeutics. V.B. is a co-founder, consultant, SAB member and has equity interest in Boundless Bio and Abterra, and the terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Bio and Orbital Therapeutics, and is an advisor to 10X Genomics, Arsenal Biosciences, Chroma Medicine and Spring Discovery.
